Navigation Links
Digestive acid production dependent on newly found hormone

A newly discovered hormone has been found to play an important role in the digestion of fat, cholesterol, and fat-soluble vitamins, such as vitamins A, E, and D. The hormone is found to control the production of bile acid by sending signals to the liver//.

The bile acids play a very important role in the emulsification of fats that enables absorption. The hormone is called fibroblast growth factor (FGF 15), the secretion of which depends on the level of bile acid secretion. FGF15 in turn limits further production of bile acid by the liver by negative feedback mechanism.

Bile acids are powerful detergents; the concentrations must be tightly regulated for proper functioning of the human body. The body needs enough quantity of the bile acid to absorb fat and other nutrients. However, too much can damage tissues and organs. This new mechanism probably holds the key to protect the body from the effects of over production of the bile acid.

Researchers have identified a receptor that senses bile acid and responds by secreting FGF15. In the liver, the secreted intestinal protein limits the activity of an enzyme called cholesterol 7a-hydroxylase (CYP7A1) critical to bile acid production. Animal models lacking FGF15 were found to have increased CYP7A1 activity and excrete greater quantities of bile acid.

The results of the present study have valuable clinical implications. For example, the above mentioned feedback mechanism might be an explanation to the liver damage associated with intravenous infusion of nutrients.

The findings also raise additional questions about the role that the circulating hormone may play in other parts of the body. An additional insight into cholesterol-derived bile acids might also yield important clues regarding cholesterol control. However, further studies in human beings are needed at the moment.
'"/>




Page: 1

Related medicine news :

1. Breast-fed Children Weather Digestive Disease
2. Obesity: Digestive Disorders Come In The Way Of Exercise
3. Silence Puts Comfort For Digestive Syndrome
4. Many Irish in the Grips of Digestive Disorders
5. Bioengineering production strains - Microbia develops new methods
6. Roche confirms Tamiflu production talks in US
7. Pigs have another utility: production of healthy oils!
8. WHO takes initiative to fight corruption tainted medicine production-supply chain
9. Adult bone health is dependent on lifestyle we live
10. Religious sensitivity of medicos gender-dependent
11. Time for Bono to Rock The Independent For AIDS Awareness
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, ... its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a ... effective management of complex spine deformity cases, particularly in children. , GSO’s focus ...
(Date:4/24/2017)... Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... their efforts to encourage sustainability, innovate new strategies to reduce waste, and support renewable ... herbal remedy provider. They look to nature to find solutions for health issues, and ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The California Dental ... in charitable dental services to 1,961 people during the April 22-23 event at the ... charge to Californians who experience barriers to care, CDA Cares educates the public and ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... ... brain tumors are expected to be diagnosed globally; approximately 25,000 of them will ... are anticipating greater use of this type of healthcare model in the diagnosis ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. , ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical ... ("Precision Lens"), today announced the signing of a ... Precision Lens will deploy a dedicated sales team ... in the U.S., primarily focused in 13 states ...
Breaking Medicine Technology: